OUTLOOK THERAPEUTICS INC (OTLK) Stock Price, Quote, News and Overview
NASDAQ:OTLK - Nasdaq - US69012T3059 - Common Stock - Currency: USD
OTLK Quote, Performance and Key Statistics
1.45
+0.08 (+5.84%)
The current stock price of OTLK is 1.45 USD. In the past month the price decreased by -2.03%. In the past year, price decreased by -82.25%.
OTLK Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.09 | 306.02B | ||
| AMGN | AMGEN INC | 13.99 | 149.08B | ||
| GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
| ARGX | ARGENX SE - ADR | 320.54 | 36.40B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.89B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
| NTRA | NATERA INC | N/A | 20.02B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
| BIIB | BIOGEN INC | 7.2 | 17.36B |
Related stock screener links
About OTLK
Company Profile
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. The company is headquartered in Iselin, New Jersey and currently employs 23 full-time employees. The company went IPO on 2016-06-13. The firm is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. The company is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Company Info
OUTLOOK THERAPEUTICS INC
111 S. Wood Avenue, Unit #100
Iselin NEW JERSEY 08852 US
CEO: Lawrence A. Kenyon
Employees: 24
Company Website: https://outlooktherapeutics.com/
Investor Relations: http://ir.outlooktherapeutics.com/
Phone: 16096193990
OUTLOOK THERAPEUTICS INC / OTLK FAQ
What is the stock price of OUTLOOK THERAPEUTICS INC today?
The current stock price of OTLK is 1.45 USD. The price increased by 5.84% in the last trading session.
What is the ticker symbol for OUTLOOK THERAPEUTICS INC stock?
The exchange symbol of OUTLOOK THERAPEUTICS INC is OTLK and it is listed on the Nasdaq exchange.
On which exchange is OTLK stock listed?
OTLK stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for OUTLOOK THERAPEUTICS INC stock?
12 analysts have analysed OTLK and the average price target is 10.71 USD. This implies a price increase of 638.62% is expected in the next year compared to the current price of 1.45. Check the OUTLOOK THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is OUTLOOK THERAPEUTICS INC worth?
OUTLOOK THERAPEUTICS INC (OTLK) has a market capitalization of 47.30M USD. This makes OTLK a Nano Cap stock.
How many employees does OUTLOOK THERAPEUTICS INC have?
OUTLOOK THERAPEUTICS INC (OTLK) currently has 24 employees.
What are the support and resistance levels for OUTLOOK THERAPEUTICS INC (OTLK) stock?
OUTLOOK THERAPEUTICS INC (OTLK) has a resistance level at 1.46. Check the full technical report for a detailed analysis of OTLK support and resistance levels.
Should I buy OUTLOOK THERAPEUTICS INC (OTLK) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of OTLK, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of OTLK, evaluating the profitability, health, valuation and growth aspects
- OUTLOOK THERAPEUTICS INC (OTLK) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- OUTLOOK THERAPEUTICS INC (OTLK) Sales and EPS estimates to see what analysts future expectations are.
- OUTLOOK THERAPEUTICS INC (OTLK) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- OUTLOOK THERAPEUTICS INC (OTLK) Insider and Institutional Ownership to learn about the owners and their transactions.
- OUTLOOK THERAPEUTICS INC (OTLK) Stock Chart to make your own analysis
- OUTLOOK THERAPEUTICS INC (OTLK) Latest news and press-releases to stay up to date.
Does OUTLOOK THERAPEUTICS INC (OTLK) stock pay dividends?
OTLK does not pay a dividend.
When does OUTLOOK THERAPEUTICS INC (OTLK) report earnings?
OUTLOOK THERAPEUTICS INC (OTLK) will report earnings on 2025-05-14, before the market open.
What is the Price/Earnings (PE) ratio of OUTLOOK THERAPEUTICS INC (OTLK)?
OUTLOOK THERAPEUTICS INC (OTLK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.9).
What is the Short Interest ratio of OUTLOOK THERAPEUTICS INC (OTLK) stock?
The outstanding short interest for OUTLOOK THERAPEUTICS INC (OTLK) is 14.83% of its float. Check the ownership tab for more information on the OTLK short interest.
OTLK Technical Analysis
OTLK Financial Highlights
Over the last trailing twelve months OTLK reported a non-GAAP Earnings per Share(EPS) of -0.9. The EPS increased by 77.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -275.26% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
OTLK Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to OTLK. The Buy consensus is the average rating of analysts ratings from 12 analysts.